Virpax Pharmaceuticals, Inc. (VRPX) Financial Ratios
7 years of historical data (2018–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
N/A
—
5yr avg: 28.74
30Y Low11.0·High48.4
ROE
↓
-2364.8%
↑-253% vs avg
5yr avg: -670.3%
30Y Low-164%·High-73%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
VRPX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $425 | $40M | $94M | $182M | $1.0B | — | — | — |
| Enterprise Value | $-1512632 | $39M | $85M | $163M | $968M | — | — | — |
| P/E Ratio → | 0.00 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | — | — | 48.44 | 10.99 | 26.80 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
VRPX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
VRPX Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -2364.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| ROE | -2364.8% | -2364.8% | -164.1% | -79.4% | -73.0% | — | — | — |
| ROA | -215.8% | -215.8% | -103.7% | -72.4% | -60.7% | -1752.5% | -6341.1% | -4294.2% |
| ROIC | — | — | — | — | — | — | — | — |
| ROCE | -2367.3% | -2367.3% | -169.5% | -80.8% | -70.1% | — | — | — |
VRPX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $2M exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -4.73 | -1.15 | -0.98 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -115.31 | -115.31 | — | — | -128.88 | -28.34 | -25.53 | -175.34 |
Net cash position: cash ($2M) exceeds total debt ($0)
VRPX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.63x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 6.36x to 0.63x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.63 | 0.63 | 1.25 | 6.36 | 18.96 | 0.02 | 0.02 | 0.05 |
| Quick Ratio | 0.63 | 0.63 | 1.25 | 6.36 | 18.96 | 0.02 | 0.02 | 0.05 |
| Cash Ratio | 0.61 | 0.61 | 1.19 | 6.14 | 17.65 | 0.01 | 0.01 | 0.04 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
VRPX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Virpax Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $4M | $1M | $1M | $1M | $494515 | $521515 | $5M |
Peer Comparison
Compare VRPX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 VRPXYou | $425 | 0.0 | — | — | — | — | -2364.8% | — | — |
 NKTR | $1B | -6.7 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 PCRX | $913M | 145.1 | 9.7 | 6.7 | 79.4% | 4.6% | 1.0% | 2.3% | 3.7 |
 PRAX | $10B | -26.0 | — | — | — | — | -45.8% | -65.0% | — |
 ABBV | $385B | 91.8 | 15.9 | 21.6 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 PFE | $149B | 19.2 | 10.6 | 16.4 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 MRK | $293B | 16.3 | 11.2 | 23.7 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
 IQV | $31B | 23.2 | 13.1 | 15.1 | 26.3% | 14.0% | 21.4% | 8.7% | 4.7 |
 CRL | $9B | -62.1 | 12.7 | 16.8 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
 SAVA | $64M | -2.5 | — | — | — | — | -17.2% | -634.1% | — |
 ATHA | $17M | -0.2 | — | — | — | — | -290.8% | — | — |
| Healthcare Median | — | 22.7 | 14.1 | 18.6 | 64.0% | -4.3% | -32.3% | -11.1% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
What if you invested $1,000 in VRPX 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in VRPX be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs VRPX Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationVRPX vs NKTR — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Nektar Therapeutics.
Compare NowVRPX — Frequently Asked Questions
Quick answers to the most common questions about buying VRPX stock.
What is Virpax Pharmaceuticals, Inc.'s P/E ratio?
Virpax Pharmaceuticals, Inc.'s current P/E ratio is 0.0x.
What is Virpax Pharmaceuticals, Inc.'s ROE?
Virpax Pharmaceuticals, Inc.'s return on equity (ROE) is -2364.8%. The historical average is -105.5%.
Is VRPX stock overvalued?
Based on historical data, Virpax Pharmaceuticals, Inc. is trading at valuation metrics that vary. Compare with industry peers and growth rates for a complete picture.